Who Owns Bridion?

Bridion is produced within Merck's sustainability framework. Merck has committed to carbon neutrality across operations by 2030 and net-zero emissions across its value chain by 2045, aligned with Science Based Targets initiative guidelines. The company aims to reduce Scope 1 and 2 emissions by 25% and Scope 3 emissions by 30% by 2030 from a 2019 baseline.

Bridion manufacturing sites participate in Merck's environmental programs. The Swords, Ireland facility received ISO 14001 certification in 2023 for implementing a closed-loop solvent recovery system that recycles 92% of solvents used in production. The Wilson, North Carolina site achieved carbon neutrality in 2025 through energy efficiency measures and a 30-megawatt solar array providing 85% of the facility's electricity.

Merck's supplier sustainability program requires suppliers to commit to environmental stewardship, ethical business practices, and human rights standards. The company's Access to Medicines program reached 110 million people in low and middle-income countries in 2025 with initiatives providing essential medications at reduced or no cost.

Bridion has faced regulatory challenges and safety concerns throughout its development and commercialization.

FDA Approval Delays and Rejections: The FDA rejected Bridion applications in July 2008, September 2013, and April 2015 due to concerns about hypersensitivity reactions and anaphylaxis risk. These repeated rejections created uncertainty about the medication's safety profile. The FDA finally approved Bridion in December 2015 after Merck conducted additional clinical studies and safety analyses.

Hypersensitivity and Anaphylaxis Concerns: Clinical trials reported cases of anaphylaxis and hypersensitivity reactions. One person experienced an anaphylactic reaction among 299 participants in a randomized trial. The FDA required additional safety studies and monitoring protocols, leading to specific warnings in the prescribing information.

Cardiac Safety Concerns: Bridion has been associated with cases of marked bradycardia, some resulting in cardiac arrest, occurring within minutes after administration. The FDA label includes specific warnings and recommendations for close hemodynamic monitoring during and after administration. Treatment with anticholinergic agents like atropine is recommended when clinically significant bradycardia occurs.

Contraceptive Drug Interactions: Bridion can reduce the effectiveness of hormonal contraceptives. The FDA requires doctors to advise women using hormonal contraceptives that Bridion may temporarily reduce contraceptive effectiveness, necessitating alternative birth control methods for a period after treatment.

Patent and Generic Competition: Hikma Pharmaceuticals sought FDA approval for a generic version of Bridion prior to patent expiration. Merck secured patent protection in the U.S. through January 2026 through successful court challenges. Generic competition is already present in several international markets and is expected to accelerate in the U.S. after patent expiration.